BIOMAT Database Logo BIOMAT Database Logo

Discovery of new thieno[2,3-d]pyrimidines as EGFR tyrosine kinase inhibitors for cancer treatment. 2023

Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt.

Background: EGFR has been considered a vital molecular target in cancer management. Aim: The discovery of new thieno[2,3-d]pyrimidine derivatives as EGFR tyrosine kinase inhibitors. Methods: Nine derivatives were designed, synthesized and subjected to in vitro and in silico studies. Results: Compound 7a significantly inhibited the growth of HepG2 and PC3 cells for both EGFR wild-type and EGFRT790M. Compound 7a caused a significant apoptotic effect, arresting HepG2 cells' growth in the S and G2/M phases. Docking and molecular dynamics simulation studies confirmed the correct and stable binding modes of the synthesized compounds against the active sites. Conclusion: Compound 7a is a promising dual EGFR inhibitor for cancer treatment.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000092004 Tyrosine Kinase Inhibitors Protein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES. TKI Tyrosine Kinase Inhibitors,Tyrosine Kinase Inhibitor,Tyrosine Protein Kinase Inhibitors,Inhibitors, Tyrosine Kinase,Kinase Inhibitors, Tyrosine
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
January 2012, Bioorganic & medicinal chemistry letters,
Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
January 2017, Current medicinal chemistry,
Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Development of new thieno[2,3-d]pyrimidines as dual EGFR and STAT3 inhibitors endowed with anticancer and pro-apoptotic activities.
January 2024, Bioorganic chemistry,
Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Thieno[2,3-d]pyrimidines as potential chemotherapeutic agents.
January 1979, Archiv der Pharmazie,
Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Pyrrolo[2,3-d]pyrimidines as EGFR and VEGFR kinase inhibitors: a comprehensive SAR review.
August 2023, Current medicinal chemistry,
Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
February 2017, European journal of medicinal chemistry,
Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors.
January 2021, Bioorganic & medicinal chemistry,
Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
July 2021, Bioorganic chemistry,
Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
Identification of 4-Amino-Thieno[2,3-d]Pyrimidines as QcrB Inhibitors in Mycobacterium tuberculosis.
September 2019, mSphere,
Eman A Sobh, and Mohammed A Dahab, and Eslam B Elkaeed, and Aisha A Alsfouk, and Ibrahim M Ibrahim, and Ahmed M Metwaly, and Ibrahim H Eissa
[Thieno[2,3-d]pyrimidines as antagonists of the glutamate receptors].
November 2008, Die Pharmazie,
Copied contents to your clipboard!